BRAIN Wins Patent for Biological Wound Conditioning

(PresseBox) ( Zwingenberg, )
Today, biotechnology company BRAIN AG announces the granting of a European patent in the field of biotechnological wound conditioning. This new substance patent, registered under the official number EP2245150 B1, was invented by BRAIN within the scope of a BMBF supported research program (FKZ: 0313916). The patent describes a naturally-occurring novel proteolytic enzyme. This biotechnologically produced protein is now used to remove necrotic wound tissue from patients in order to facilitate rapid wound closure. The authority granted the patent application full status as a European patent. The international protection is pending.

Within the framework of the research project "Industrial production processes for novel enzymes and bio-active substances from natural sources: MikroPro", BRAIN has been actively engaged in several subprojects including biological wound conditioning.

This involved isolating and characterising a proteolytic enzyme from the larvae of the Common green bottle fly Lucilia sericata and developing its biotechnological production. This highly potent and specific proteindigesting enzyme (protease) will now be used for conditioning badly healing wounds.

According to the professional magazine "Deutsches Ärzteblatt", about 3 million people in Germany alone suffer from badly or never healing socalled chronic wounds. These include instances of Ulcus cruris, Decubitus or Diabetic foot ulcereration. Today, chronic wounds often require longterm, cost-intensive treatments and amputations are not rare.

At present, one of the difficulties of treating and healing the wound is the complete and pain-free removal of necrotic or devitalized tissue of the wound. This is where BRAIN and their method of enzymatic wound conditioning takes effect. "By identifying this natural functional principle we are able to introduce a completely new method for conditioning wounds", explains Dr. Frank Niehaus, program manager of Enzyme Technologies at BRAIN. "At the moment, we are working together with a number of leading partners to integrate the enzyme into innovative products as fast as possible, obtain international approval and therefore launch the product within the next few months", adds Dr. Michael Krohn, Unit Head BioActives at BRAIN.

"As a SME, the partial funding of this high-risk, highly innovative research project by the BMBF has given us the opportunity to realize project ideas that we would not have been able to pre-finance by ourselves", says Dr. Jürgen Eck, Head of Research at BRAIN AG. "The five year term of the support measure has also given us long-term planning security, which has definitely contributed to the success of the project."
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an